Details of Disease

General Information of Disease (ID: DISFYSIV)

Disease Name Virus infection
Synonyms
infections, Viruses; infection, viral; viral infection; viral disease; Viruses infectious disease; Viruses caused disease or disorder; virus infection; Viruses infection; viral disorder; Viruses disease or disorder
Disease Class 1A24-1D9Z: Virus infection
Definition Any disease caused by a virus.
Disease Hierarchy
DISH7H5I: Human disease
DISEM33Q: Infectious disease
DISFYSIV: Virus infection
ICD Code
ICD-11
ICD-11: 1A24-1D9Z
Expand ICD-9
054.0,054.1,054.2,054.3,075,771.2,052,053

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)
This Disease is Treated as An Indication in 21 Approved Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
ACAM-2000 DM3S8TI Approved NA [1]
Aciclovir DMYLOVR Approved Small molecular drug [2]
Arbidol DMOQK8Z Approved Small molecular drug [1]
Chromic Chloride DMOE9GQ Approved Small molecular drug [1]
CVT-E002 DMXFY9R Approved NA [1]
Epervudine DMK6E0C Approved Small molecular drug [1]
Famciclovir DMJHLSD Approved Small molecular drug [3]
Ganciclovir DM1MBYQ Approved Small molecular drug [3]
Immune globulin DMX2OMJ Approved NA [1]
Imvamune smallpox vaccine DMEJRZF Approved NA [4]
Inosine pranobex DM2P6R0 Approved Small molecular drug [1]
Lasofoxifene DMHA18P Approved Small molecular drug [5]
LC16m8 DMG43OF Approved NA [6]
Menomune DME5HB5 Approved NA [1]
Ridostin DMLCEGC Approved Small molecular drug [1]
Sorivudine DMUJGR1 Approved Small molecular drug [1]
Tecovirimat DMW5ML9 Approved NA [7]
Trifluridine DMG2YBD Approved Small molecular drug [8]
Valaciclovir DMHKS94 Approved Small molecular drug [9]
Valganciclovir DMS2IUH Approved Small molecular drug [10]
Zidovudine DM4KI7O Approved Small molecular drug [11]
------------------------------------------------------------------------------------
⏷ Show the Full List of 21 Drug(s)
This Disease is Treated as An Indication in 21 Clinical Trial Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
ACAM-1000 DMKXFDX Phase 3 NA [12]
CJ-50300 DMGIZ4R Phase 3 NA [13]
Hebergel DMQTLVB Phase 3 NA [14]
Netivudine DMTKRY1 Phase 3 Small molecular drug [15]
Synthetic hypericin DMXU4ON Phase 3 NA [16]
EISO DMKPVA5 Phase 2 NA [17]
Epetirimod DMG3FAD Phase 2 Small molecular drug [18]
PLECONARIL DMK10ZC Phase 2 Small molecular drug [19]
RSV-604 DMAJH75 Phase 2 Small molecular drug [20]
Rupintrivir DMVCXZK Phase 2 Small molecular drug [21]
Valopicitabine dihydrochloride DMFWZ2U Phase 2 Small molecular drug [22]
Viralym-M DM6355M Phase 2 Cell therapy [23]
ALAMIFOVIR DMNXLOT Phase 1/2 Small molecular drug [24]
AGS-v DMVKMH8 Phase 1 NA [25]
AVI-4020 DM6PLVI Phase 1 NA [26]
GSK2654909A DM67AMC Phase 1 NA [27]
GSK2654911A DMGGI4S Phase 1 NA [28]
N-methanocarbathymidine DM2ZPFV Phase 1 NA [11]
PEG-Interferon lambda (IL-29) DMMEPKR Phase 1 NA [29]
ROCICLOVIR DMDRBNJ Phase 1 Small molecular drug [30]
RSV/PIV-3 vaccine DMNWEGV Phase 1 NA [31]
------------------------------------------------------------------------------------
⏷ Show the Full List of 21 Drug(s)
This Disease is Treated as An Indication in 2 Patented Agent(s)
Drug Name Drug ID Highest Status Drug Type REF
Oxetane 3,3-dicarboxamide compound 1 DMSB09X Patented Small molecular drug [32]
Oxetane 3,3-dicarboxamide compound 2 DMMCTAK Patented Small molecular drug [32]
------------------------------------------------------------------------------------
This Disease is Treated as An Indication in 28 Discontinued Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Bropirimine DMMT1YQ Discontinued in Phase 3 Small molecular drug [33]
Lobucavir DM8OMI6 Discontinued in Phase 3 Small molecular drug [34]
A-5021 DMX56G4 Discontinued in Phase 2 Small molecular drug [35]
A-75925 DMF4MRD Discontinued in Phase 2 Small molecular drug [36]
ChimeriVax-West Nile DMXBKIW Discontinued in Phase 2 NA [37]
Epstein-Barr vaccine DMAEJJZ Discontinued in Phase 2 NA [38]
M-114 DM542XV Discontinued in Phase 2 NA [39]
MVA3000 DMPMV0A Discontinued in Phase 2 NA [40]
PIRODAVIR DM3ISKB Discontinued in Phase 2 Small molecular drug [41]
R-61837 DMJTOP8 Discontinued in Phase 2 Small molecular drug [42]
T611 DMDN3TV Discontinued in Phase 2 NA [43]
Theradigm-HBV DMGR7Y3 Discontinued in Phase 2 NA [44]
Tomeglovir DMY40KZ Discontinued in Phase 2 Small molecular drug [45]
TT-62 DMWXOJN Discontinued in Phase 2 Small molecular drug [46]
Elstree-BN DM2DI62 Discontinued in Phase 1/2 NA [47]
CHPMPC DMJ5UYL Discontinued in Phase 1 Small molecular drug [48]
CI-1013 DMEPYC1 Discontinued in Phase 1 NA [49]
Cyclocreatine DM1I7UO Discontinued in Phase 1 Small molecular drug [50]
HO-221 DMQOW8H Discontinued in Phase 1 Small molecular drug [51]
MEDI-491 DM03I93 Discontinued in Phase 1 NA [52]
Amitivir DM64YJW Terminated Small molecular drug [54]
BRL-44385 DM4E1V6 Terminated Small molecular drug [55]
C-AFG DMJQ3WR Terminated NA [56]
CL-387626 DMA4DNX Terminated NA [57]
GR-95168 DMAHNF6 Terminated NA [58]
GW-275175 DMGSN1V Terminated NA [59]
ISIS-1082 DMD6SXO Terminated NA [60]
Theradigm-HIV DML6QVV Terminated NA [61]
------------------------------------------------------------------------------------
⏷ Show the Full List of 28 Drug(s)
This Disease is Treated as An Indication in 1 Preclinical Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
MNLP-18 DMEK78T Preclinical NA [53]
------------------------------------------------------------------------------------
This Disease is Treated as An Indication in 28 Investigative Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
4pox DMCWI21 Investigative NA [11]
Acyclic nucleoside phosphonates DMFQ22I Investigative NA [11]
AK-2 DM9YSV6 Investigative Small molecular drug [11]
ALS-012117 DMYC4Y9 Investigative NA [11]
ALS-2135 DMXL3EP Investigative NA [11]
APV-001 DMGK80T Investigative NA [11]
EPB-200 DMUHD28 Investigative NA [11]
FGI-102 DMP5GN8 Investigative NA [11]
FGI-106 DMENA6O Investigative NA [11]
M102.4 DMFHABG Investigative NA [11]
MDDR 347017 DMN0GDK Investigative NA [11]
Micacides DMS1UL3 Investigative NA [11]
Nazvax-PX DM9D8XF Investigative NA [11]
Oravax-PX DMFGX77 Investigative NA [11]
OSL-95II DMIHNQL Investigative Small molecular drug [11]
P-536 DM5CR96 Investigative Small molecular drug [11]
SB-104 DMK84YL Investigative NA [11]
SOM-0003 DMYCT1X Investigative NA [11]
SOM-0005 DMSBCDV Investigative NA [11]
SOM-0010 DMI7Q2C Investigative NA [11]
SOM-0856 DMDUB43 Investigative NA [11]
SQ-609 DMY9J88 Investigative Small molecular drug [11]
ST-148 DMUQBJC Investigative Small molecular drug [11]
ST-669 DMGMABW Investigative NA [11]
T-1106 DMPA2E9 Investigative Small molecular drug [62]
VennVax DM7VPOR Investigative NA [11]
Viroprev DMXX23U Investigative NA [11]
XG-5XX DMCYD81 Investigative NA [11]
------------------------------------------------------------------------------------
⏷ Show the Full List of 28 Drug(s)

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4829).
3 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
4 Clinical pipeline report, company report or official report of Bavarian Nordic.
5 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026623)
6 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018232)
7 ClinicalTrials.gov (NCT02474589) A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of the Anti-Orthopoxvirus Compound Tecovirimat.
8 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8697).
9 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4824).
10 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4716).
11 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
12 ACAM2000: the new smallpox vaccine for United States Strategic National Stockpile. Drug Des Devel Ther. 2010 May 25;4:71-9.
13 ClinicalTrials.gov (NCT01056770) Safety and Efficacy of CJ Smallpox Vaccine in Healthy Volunteers. U.S. National Institutes of Health.
14 Detection of PEGylated proteins in polyacrylamide gels by reverse staining with zinc and imidazole salts. Electrophoresis. 2008 Jun;29(11):2363-71.
15 ClinicalTrials.gov (NCT00002315) A Comparison of 882C87 Versus Acyclovir in the Treatment of Herpes Zoster in Patients With Weakened Immune Systems. U.S. National Institutes of Health.
16 ClinicalTrials.gov (NCT02448381) Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides). U.S. National Institutes of Health.
17 ClinicalTrials.gov (NCT01286441) A Phase 2 Trial of East Indian Sandalwood Oil in the Treatment of Common Warts (Verruca Vulgaris). U.S. National Institutes of Health.
18 ClinicalTrials.gov (NCT00312286) Efficacy of 851B Gel for Treating High-Risk Cervical Human Papillomavirus Infection in Women.. U.S. National Institutes of Health.
19 ClinicalTrials.gov (NCT00031512) Pleconaril Enteroviral Sepsis Syndrome. U.S. National Institutes of Health.
20 Mechanism of action for respiratory syncytial virus inhibitor RSV604. Antimicrob Agents Chemother. 2015 Feb;59(2):1080-7.
21 In Vitro Resistance Study of Rupintrivir, a Novel Inhibitor of Human Rhinovirus 3C Protease . Antimicrob Agents Chemother. 2007 December; 51(12): 4366-4373.
22 ClinicalTrials.gov (NCT00395421) Study to Evaluate Drug-drug Interaction Between Valopicitabine and Ribavirin. U.S. National Institutes of Health.
23 ClinicalTrials.gov (NCT04693637) Study of Viralym-M (ALVR105) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant. U.S. National Institutes of Health.
24 Koinfektion Hepatitis und HIV, Stefan Mauss. Page(75).
25 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
26 ClinicalTrials.gov (NCT00387283) Pharmacokinetic Study in Cerebral Spinal Fluid After a Single Dose of AVI-4020. U.S. National Institutes of Health.
27 ClinicalTrials.gov (NCT01659086) Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccines GSK2654911A and GSK2654909A Administered to Adults 18 to 64 Years of Age. U.S. National Institutes of Health.
28 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800036655)
29 ClinicalTrials.gov (NCT00565539) Study of PEG-rIL-29 (or PEG-IFN Lambda) in Subjects With Chronic Hepatitis C Virus Infection. U.S. National Institutes of Health.
30 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001059)
31 Phase 1 study of the safety and immunogenicity of a live, attenuated respiratory syncytial virus and parainfluenza virus type 3 vaccine in seronegative children. Pediatr Infect Dis J. 2012 Feb;31(2):109-14.
32 VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Sep;27(9):987-1004.
33 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000744)
34 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002213)
35 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009510)
36 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003337)
37 Recent progress in West Nile virus diagnosis and vaccination. Vet Res. 2012 Mar 1;43:16.
38 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009599)
39 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009436)
40 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021561)
41 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001224)
42 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001063)
43 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011676)
44 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004156)
45 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012718)
46 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002433)
47 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025286)
48 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004825)
49 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007002)
50 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5491).
51 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000797)
52 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002168)
53 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026397)
54 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001039)
55 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002837)
56 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003394)
57 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013835)
58 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003388)
59 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010110)
60 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001244)
61 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4917).
62 Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106. Antimicrob Agents Chemother. 2009 Jan;53(1):202-9.
63 Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.